


### 1 Figures




Supplementary Figure 1S: Sedation scores after acoustic stimulation with a clicker following single oral administration of cannabidiol (CBD) paste in escalating doses (0.2 mg CBD/kg; 1 mg CBD/kg; 3 mg CBD/kg) - comparison between values obtained on baseline and trial day for the treatment and control group. Higher scale points relate to a higher level of sedation (Table 1).




Supplementary Figure 2S: Sedation scores after acoustic stimulation with a plastic bag following single oral administration of cannabidiol (CBD) paste in escalating doses (0.2 mg CBD/kg; 1 mg CBD/kg; 3 mg CBD/kg) - comparison between values obtained on baseline and trial day for the treatment and control group. Higher scale points relate to a higher level of sedation (Table 1).




Supplementary Figure 3S: Sedation scores after visual stimulation with a pink cloth following single oral administration of cannabidiol (CBD) paste in escalating doses (0.2 mg CBD/kg; 1 mg CBD/kg; 3 mg CBD/kg) - comparison between values obtained on baseline and trial day for the treatment and control group. Higher scale points relate to a higher level of sedation (Table 1).



Supplementary Figure 4S: Heart rates (beats per minute (bpm)) prior to single oral administration of cannabidiol (CBD) in three escalating doses (0.2 mg CBD/kg BW; 1 mg CBD/kg BW; 3 mg CBD/kg BW), displayed in 15-minute sections over 12 hours. Due to technical issues, the trial 1 R-R-interval data are partly incomplete.



Supplementary Figure 5S: Root mean square of successive R-R interval differences (RMSSD) in milliseconds (ms) prior to single oral administration of cannabidiol (CBD) in three escalating doses (0.2 mg CBD/kg BW; 1 mg CBD/kg BW; 3 mg CBD/kg BW), displayed in 15-minute sections over 12 hours. Due to technical issues, the trial 1 R-R-interval data are partly incomplete.



Supplementary Figure 6S: Standard deviations of R-R intervals (SDNN) in milliseconds (ms) prior to single oral administration of cannabidiol (CBD) in three escalating doses (0.2 mg CBD/kg BW; 1 mg CBD/kg BW), displayed in 15-minute sections over 12 hours. Due to technical issues, the trial 1 R-R-interval data are partly incomplete.

### 2 Tables

Supplementary Table 1S: Examples of the facial expression scale (Table 2).



## **Orbital opening**

2 Eyes completely open

### **Position of ears**

2 Pointed, position of attention

### **Chewing muscles**

2 Moderately present


### Lips

2 Loose touching of lips

### Nostrils

1 Dilated, outer ring clearly visible





### **Orbital opening**

2 Eyes completely open

### **Position of ears**

2 Pointed, position of attention

### **Chewing muscles**

2 Moderately present

### Lips

2 Loose touching of lips

### Nostrils

2 Non-dilated nostrils

Total sum: 10



## **Orbital opening**

3 Eyes partially open (> 50%)

### **Position of ears**

3 Asymmetrical; one ear hanging

## **Chewing muscles**

2 Moderately present


## Lips

2 Loose touching of lips

### Nostrils

3 Small nostrils, relaxed outer ring

Total sum: 13



### **Orbital opening**

4 Eyes almost/completely closed (< 50%)

### **Position of ears**

4 Wide opening between ear tips

## **Chewing muscles**

2 Moderately present

## Lips

4 Pronounced relaxation/hanging of one lip

### Nostrils

2 Non-dilated nostrils

Total sum: 16



## **Orbital opening**

4 Eyes almost/completely closed (< 50%)

## **Position of ears**

4 Wide opening between ear tips

# **Chewing muscles**

3 Not present

## Lips

3 Slight relaxation of one lip

### Nostrils

3 Small nostrils, relaxed outer ring

Total sum: 17